Open AccessThe Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients
Author(s) -
Zeynel Abidin Sayıner,
Gamze Inan Demiroğlu,
Ersin Akarsu,
Mustafa Araz
Publication year - 2020
Publication title -
turkish journal of pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.241
H-Index - 14
eISSN - 2148-6247
pISSN - 1304-530X
DOI - 10.4274/tjps.galenos.2018.83788
Subject(s) - sitagliptin , hyperamylasemia , medicine , saxagliptin , pancreatitis , amylase , postprandial , gastroenterology , vildagliptin , acute pancreatitis , lipase , endocrinology , diabetes mellitus , type 2 diabetes mellitus , metformin , enzyme , biochemistry , chemistry
In different studies, it has been shown that the use of dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4 inh) does not increase the risk of pancreatitis or pancreatic cancer. Although the number of studies involving clinical pancreatitis clinics is sufficient, the number of studies involving clinical non-pancreatitis hyperamylasemia is rare. The aim of the study was to investigate the relationship between DPP-4 inh usage and amylase and lipase increment without clinical pancreatitis symptoms.